-
Mashup Score: 0Updates on the use of molecular monitoring to detect MRD in AML - 8 month(s) ago
Laura Dillon, PhD, FACMG, National Institutes of Health, Bethesda, MD, talks on the use of molecular monitoring in acute myeloid leukemia (AML), commenting on efforts to translate next-generation sequencing (NGS) measurable residual disease (MRD) testing to the clinic. Dr Dillon also discusses aims to standardize MRD testing in this disease setting and highlights ongoing trials investigating MRD-directed interventions. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The VJSessions | VJHemOnc - 8 month(s) ago
Roundtable discussions with leading experts in hematological oncology
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more - 8 month(s) ago
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics - 8 month(s) ago
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the Phase I COVALENT-101 study (NCT05153330), which is investigating a novel covalent menin inhibitor (BMF-219) in patients with acute myeloid leukemia (AML). Dr Ravandi also highlights other studies which have demonstrated positive outcomes with the use of menin inhibitors in patients with specific subsets of AML. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 | Vincerx Pharma - 8 month(s) ago
Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL PALO ALTO, Calif. , Sept. 14, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through
Source: investors.vincerx.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution - 8 month(s) ago
In recent years, the therapeutic landscape of myeloid malignancies has been completely revolutionized by the introduction of several new drugs, target…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4VJHemOnc – The video journal of hematological oncology - 8 month(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @VJHemOnc: What's new in the WHO and ICC classifications of AML? @sanamloghavi just gave us a great summary! 👉https://t.co/XFFSSiEpVJ👈…
-
It's always great catching up with Valeria Santini! Stay tuned for everything #MDS 👉https://t.co/Jvj1Z7sRDR👈 @UNI_FIRENZE @SocietyofHemOnc #SOHO2023 #SOHO23 #MyelodysplasticSyndromes #MDSsm #HemOnc https://t.co/C3vRPxB2I3
-
-
Mashup Score: 0VJHemOnc – The video journal of hematological oncology - 8 month(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Long-term follow-up post hoc analysis of sorafenib maintenance therapy after allo-HSCT in patients with FLT3-mutated AML - 8 month(s) ago
We summarize the long-term follow-up results of a post hoc study from a phase III trial investigating sorafenib maintenance after allo-HSCT in patients with FLT3-mutated AML.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
It was a pleasure to speak with @LauraWDillon (@nih_nhlbi) at #SOHO23, who shared some insights into the use of molecular monitoring in AML & highlighted the importance of standardizing MRD testing in this disease: 🎥 https://t.co/apk6ZRGQ8v #AMLsm #LeuSM #HemOnc